Dental Tribune Asia Pacific

Biodentine opens new treatment option allowing more teeth to be saved!

By Septodont
September 24, 2019

SAINT-MAUR-DES-FOSSÉS, France: Launched nearly ten years ago, Biodentine has become a must-have product when it comes to vital pulp therapy. Acknowledged by more than 600 publications worldwide, Biodentine has allowed millions of teeth to be saved from around the globe. Today, a new door opens for teeth showing irreversible pulpitis–a condition that until now had doomed teeth to root canal treatment.

Following a position statement made from the European Society of Endodontogy regarding the management of exposed pulp, supported by three clinical studies run over the past 3 years showing 95% clinical success and validated by Septodont’s notified body; Biodentine can now securely be used for teeth showing signs and symptoms of irreversible pulpitis, as long as hemostasis can be achieved within 5 minutes. This could represent not less than 85% of the cases.

Thanks to its one-of-a-kind properties, dentists can extend vital pulp therapy using Biodentine to irreversible pulpitis conditions, which allows complete dentin bridge formation. The treatment is minimally invasive, preserving as much tooth structure as possible. The patient is immediately relieved from the pain associated with the inflammation. The bio “bulk-fill” procedure of Biodentine allows the practitioner to use only one material to fill the cavity, making it easier to use.

*If hemostasis cannot be achieved after full pulpotomy, a pulpectomy and a RCT should be carried out, provided the tooth is restorable (ESE Position Paper, Duncan et al. 2017).

 

Comments are closed here.

Latest Issues
E-paper

DT Asia Pacific No. 4, 2019

Open PDF Open E-paper All E-papers

© 2019 - All rights reserved - Dental Tribune International